

Fax Completed form to Navitus at: 855-668-8552 For questions, please call: 866-270-3877

Coverage Determination Request Form Nebulized Medications

		Request Info	ormation (required)			
This request is:						
Expedited	I* (Urgent) (decision	n within 24 hours)				
Standard ■ Standard	(Non-Urgent) (dec	ision within 72 hours	2)			
*If the requestor or prescriber believe that waiting 72 hours for a standard decision could seriously harm the member's life, health, or ability to regain maximum function, an expedited (fast) decision can be requested. If the prescriber indicates that waiting 72 hours could seriously harm the member's health, a decision will automatically be made within 24 hours. If the prescriber's support for an expedited request is not obtained, the request will be reviewed to determine if a fast decision is required.						
process. If the request be processed without of	is asking for an EXCE one. Please submit all I	PTION, the prescriber I	MUST provide a statem	nent suppor standard CN	ting the req	ole will delay the review uest and the request cannot AGE DETERMINATION uire supporting information.
Memb	er Information (requ	ired)	Pre	scriber Inf	ormation	(required)
Member Name:			Prescriber Name:			
Member Insurance ID #:			NPI#:		Specialty:	
Date of Birth:			Office Phone:			
Member Phone:			Office Fax:			
Member Street Address:			Office Street Address:			
City:	State:	Zip:	City:	State:		Zip:
	Requestor Inform	nation (required if no	ot requested by the	member o	r prescrib	er)
An individual other than the member or prescriber (such as a family member or friend) may make a request on behalf of the member provided that the individual is a representative. Documentation must be attached showing the individual's authority to represent the member (a completed Authorization of Representation Form CMS-1696 or a written equivalent). For more information on appointing a representative, contact the plan or 1-800-Medicare.						
Requestor Name:			Requestor Phone:			
Requestor Address:			Relationship to Member:			
City:		State:		Zip:		

Nebulized Medications_NVT_2023 Version: 1.0

Please fill out the following information:

1. Indicate Medication Requested: (NOTE: Drugs below are a representative list, only. See plan formulary to verify coverage status.) acetylcysteine (MUCOMYST) (Go to #2) albuterol sulfate inhalation solution (Go to #2) albuterol / ipratropium inhalation solution (DUONEB) (Go to #2) arformoterol tartrate (BROVANA) (Go to #2) budesonide (PULMICORT) (Go to #2) cromolyn sodium inhalation solution (INTAL) (Go to #2) dornase alfa (PULMOZYME) (Go to #2) formoterol fumarate (PERFOROMIST) (Go to #2) ipratropium bromide inhalation solution (ATROVENT) (Go to #2) levalbuterol hydrochloride nebulizer solution (XOPENEX) (Go to #2) pentamidine isethionate (NEBUPENT / PENTAM) (Go to #2) tobramycin nebulizer solution (TOBI / KITABIS) (Go to #2)

Other

(Go to #2)

iloprost (VENTAVIS)

Nebulized Medications_NVT_2023

Version: 1.0

2.	Quantity Prescribed: (Go to #3)
3.	Dosage Form: (Go to #4)
4.	Strength & Route of Administration: (Go to #5)
5.	Directions for Use (include frequency and expected length of therapy): (Go to #6)
B vs.	D Primary Billing Determination (required)
6.	Please indicate how the medication is being administered: Via Nebulizer (Go to #8) Other (Go to #7)

Nebulized Medications_NVT_2023 Version: 1.0

7.	Please provide route of administration: (complete Part D Coverage Determination Criteria below) (Go to #9)
8.	Please indicate where the member resides: Nursing Facility/Long-Term Care (complete Part D Coverage Determination Criteria below) (Go to #9) Home Setting (Bill to Medicare Part B) (END)
Part	D Coverage Determination Criteria (required)
9.	Provide primary diagnosis including ICD-10 Code(s): (Go to #10)

Nebulized Medications_NVT_2023 Version: 1.0

10.	What condition is the drug being used for? Prescribed for the management of cystic fibrosis in an adult or pediatric member 6 years of age or older with Pseudomonas aeruginosa (tobramycin nebulizer solution (TOBI / KITABIS) ONLY)			
	(Go to #13)			
	Prescribed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (New York Heart Association (NYHA) Class), and lack of deterioration (VENTAVIS ONLY)			
	(Go to #12)			
	Other (Go to #11)			
11.	If being prescribed for an indication not listed above, please provide any additional clinical information important to this review: (Go to #13)			
Pulm	onary Arterial Hypertension (PAH)			
12.	Is the diagnosis confirmed by right heart catheterization?	Yes	No	
		(Go to #13)	(Go to #13)	

Infor	mation Gathering		
13.	Are there any other comments, diagnoses, symptoms, medications tried or failed (including dates of drug trials and results of previous drug trials), drug allergies and/or any other pertinent information the physician feels is important to this review? (If yes, please explain below)	Yes (Go to #14)	No (Go to #14)

Exception Requests (optional)

14. If the request is not for a prior authorization, please indicate the request type: (The prescriber MUST provide a statement supporting the request. Requests cannot be processed without one.)

N/A - Not an exception request

(Go to #21)

The member has been using a drug that was previously included on the plan's list of covered drugs, but is being removed or was removed from the list during the plan year.

(Go to #15)

The request is for an exception to the plan's limit on the number of pills (quantity limit) the member can receive so that the member can get the number of pills the prescriber prescribed.

(Go to #15)

The drug plan charges a higher copayment for the drug the prescriber prescribed than it charges for another drug that treats the member's condition, and the member wants to pay the lower copayment.

(Go to #15)

The member has been using a drug that was previously included on a lower copayment tier, but is being moved to or was moved to a higher copayment tier.

(Go to #15)

The drug plan charged the member a higher copayment for a drug than it should have.

(Go to #15)

The member wants to be reimbursed for a covered prescription drug that they paid for out of pocket.

(Go to #15)

15.	Do you believe one or more of the prior authorization requirements should be waived? (If yes, you must provide a statement explaining the medical reason why the exception should be approved.)	Yes (Go to #16)	No (Go to #16)
16.	Would this medication likely be the most effective option for this member? (If yes, please explain below)	Yes (Go to #17)	No (Go to #17)
17.	Is the member currently being treated for the condition(s) requiring the requested drug? (If yes, please explain the member's current drug regimen for the condition(s) below)	Yes (Go to #18)	No (Go to #18)
18.	If the member is currently using this medication, would changing the current regimen likely result in adverse effects for the member? (If yes, please explain below)	Yes (Go to #19)	No (Go to #19)
19.	Are there any concerns for a drug interaction with the addition of the requested drug to the member's current drug regimen? (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)	Yes (Go to #20)	No (Go to #20)

Version: 1.0

20.	Are there any FDA noted contraindications to the requested drug? (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)	Yes (Go to #21)	No (Go to #21)	
Additional Information				
21.	Please provide any additional information we should consider (or attach a (END)	ny supporting doc	uments):	
	Submission Information (required)			

Please Note:

Signature: _____

- This request may be denied or dismissed unless all required information is received.
- The prescriber's office will receive a response via fax.
- For urgent requests, please call the phone number listed below.
- For real time submission 24/7 please visit the secure prescriber portal on our plan's website for the appropriate form and instructions on how to submit your request.
- Requests can also be initiated via phone, or the form may be sent via fax or mail:

Phone Number: (866) 270-3877

Fax Number: (855) 668-8552
Mailing Address: ATTN: PRIOR AUTHORIZATION

P.O. Box 1039

Appleton, WI 54912-1039

Authorization Period: 1 Year

PLEASE FAX COMPLETED FORM TO: 855-668-8552

Nebulized Medications_NVT_2023

Version: 1.0

Date: _____

Coverage Determination Request Form Nebulized Medications

<u>Fax Confidentiality Notice:</u> The information contained in this transmission is confidential, proprietary, or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). This message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to civil or criminal penalties. If you received this transmission in error, please notify us immediately by telephone at (866) 270-3877.

This request may be denied or dismissed unless all required information is received. The prescriber's office will receive a response via fax. For urgent requests, please call the phone number listed below. For real time submission 24/7 please visit the secure prescriber portal on our plan's website for the appropriate form and instructions on how to submit your request. Requests can also be initiated via phone or the form may be sent via fax or mail: Phone Number: (866) 270-3877, Fax Number: (855) 668-8552, Mailing Address: ATTN: PRIOR AUTHORIZATION, P.O. Box 1039 Appleton, WI 54912-1039.

Nebulized Medications_NVT_2023 Version: 1.0